TheraRadar
Data updated: Jun 17, 2026

TERCONAZOLE

Infectious Disease Approved 2004-04-06

Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures.

Source: FDA Label • SUN PHARMA CANADA
7
Indications
--
Phase 3 Trials
22
Years on Market

Details

Status
Prescription
First Approved
2004-04-06
Routes
VAGINAL
Dosage Forms
SUPPOSITORY, CREAM

TERCONAZOLE Approval History

2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
18 FDA actions from 2004 to 2025
Aug 2025 SUPPL
Label · Labeling
Feb 2016 SUPPL
Label · Labeling
Feb 2016 SUPPL
Label · Labeling

What TERCONAZOLE Treats

7 FDA approvals

Originally approved for its first indication in 2004 . Covers 7 distinct patient populations.

  • Other (7)
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT02308007 SMART GIVES results posted MTC-001 (Trial 3) Ph 3 completed Multi-Center Study of New Medications to Treat Vaginal Infections
NCT02308046 SMART GIVES results posted MTC-001 (Trial 1) Ph 3 completed Multi-Center Study of New Medications to Treat Vaginal Infections
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TERCONAZOLE FDA Label Details

Indications & Usage

FDA Label (PDF)

Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures.

Looking for the branded version?

TERAZOL 3

Full clinical data, patents, trials, and competitive landscape for terconazole.

See TERAZOL 3

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.